Plasma Prokineticin 1, a prognostic biomarker in colorectal cancer patients with curative resection: a retrospective cohort study

Abstract Background Prokineticin 1 (PROK1) was reported as an angiogenic factor, which is associated with tumor progression, cell invasion, and metastasis in colorectal cancer. Although the association between PROK1 expression in primary cancer lesion and patient prognosis was reported, it is unclear whether plasma PROK1 concentration may be a predictive factor in colorectal cancer patients. This study investigated the association between PROK1 concentration in plasma and prognosis in colorectal cancer patients. Methods We measured preoperative PROK1 plasma levels using ELISA method, while PROK1 expression in primary cancer lesion was evaluated using immunohistochemistry (IHC). The association between plasma PROK1 levels and cancer-related survival rate (CRS) was evaluated. Additionally, we examined whether simultaneous PROK1 expression in both primary cancer lesions and plasma was correlated with CRS. The cancer-related survival rate was calculated using the Kaplan-Meier method, and survival estimates were compared using the log-rank test. Results We have gathered eligible 130 CRC patients retrospectively. Out of 130 patients, 61 (46.9%) were positive on IHC in primary cancer, and 69 (53.1%) were negative, while 43 (33.1%) had high-value PROK1 in plasma. Out of these 43, 30 (25.4%) also had concomitant higher IHC expression in primary cancer. The plasma PROK1 levels tended to increase with advancing stages. The plasma PROK1-positive group had a lower 5-year CRS than the negative group (63.6% vs. 88.2%; P = 0.006). Additionally, simultaneous PROK1 expression was associated with a more significant decrease of 5-year CRS than both negative groups in all stages (76.2% vs. 92.5%; P = 0.003) and stage III (59.3% vs. 84.5%; P = 0.047). Multivariate analysis showed simultaneous PROK1 expression was independently associated with worse CRS (HR, 1.97; 95% CI 1.20‑3.24, P < 0.01). Conclusion PROK1 expression in preoperative plasma reflects poor prognosis in patients undergoing curative resection for colorectal cancer. The plasma PROK1 level may be a potential predictive marker, especially in stage III colorectal cancer patients.

Download Full-text

Perioperative chemotherapy with S-1 plus oxaliplatin (SOX) for stage III colorectal cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.4_suppl.603 ◽

2016 ◽

Vol 34 (4_suppl) ◽

pp. 603-603 ◽

Cited By ~ 1

Author(s):

Naoya Aisu ◽

Yoichiro Yoshida ◽

Akira Komono ◽

Teppei Yamada ◽

Daibo Kojima ◽

...

Keyword(s):

Colorectal Cancer ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Curative Resection ◽

Response Rate ◽

Stage Iii ◽

Perioperative Chemotherapy ◽

Safety And Efficacy ◽

Grade 3 ◽

Colorectal Cancer Patients

603 Background: Neoadjuvant chemotherapy (NAC) has a potential to increase the curative resection rate and reduce the recurrence rate. The purpose of this study was to evaluate the safety and efficacy of S-1 plus oxaliplatin (SOX) regimen as neoadjuvant (4 courses) and adjuvant (4 courses) for the treatment of patients with Stage III colorectal cancer (anyT and N+). Methods: We have treated patients with Stage III colorectal cancer undergone operation after NAC (SOX 4 courses) and adjuvant chemotherapy (SOX 4 courses) at Fukuoka University Hospital. SOX regimen (S-1 80 mg/ m2 : day1~14 and oxaliplatin 130 mg/m2 : day1) was administrated every 3 weeks. The primary endpoint was response rate and safety. Results: Of the 21 patients enrolled between September 2012 and December 2014. The median age was 62 years (range, 43–87), and 57% were female. Eastern Cooperative Oncology Group performance status scores were 0, 1, and 2 in 50%, 40%, and 10% of the patients, respectively. The patients received median 4(1-4) courses of NAC and median 4(0-4) courses of adjuvant chemotherapy. The cumulative median dose of oxaliplatin was 1204 (210-1841) mg/body. In NAC, 4 patients required treatment interruption because of the toxicity [grade2 gastrointestinal bleeding (n = 1), grade 3 thrombocytopenia (n = 2), and grade4 ileus (n = 1)]. A complete response according to Response Evaluation Criteria in Solid Tumors ver.1.1 was observed in a patient (4.8%) and a partial response was observed in 15 patients (71.4%) and a stable disease was 5 patients (23.8%). The response rate and tumor control rate were 76.1% and 100%. Curative resection was performed in all patients. No perioperative complications more than grade3 as Clavien Dindo classification was observed in all patients. The observed adverse events of Grade 3 or higher were thrombocytopenia (n = 4), neutropenia (n = 3), diarrhea (n = 1), and ileus (n = 1). Conclusions: Perioperative chemotherapy with SOX is safe and effective. Further studies are warranted to confirm the safety and efficacy of this method. A single-arm phase II trial of perioperative chemotherapy (SOX) and operation for stage III colorectal cancer patients (FUTURE1104 SOS3).

Download Full-text

Prognostic value of pre- and post-operative circulating tumor cells detection in colorectal cancer patients treated with curative resection: a prospective cohort study based on ISET device

Cancer Management and Research ◽

10.2147/cmar.s176575 ◽

2018 ◽

Vol Volume 10 ◽

pp. 4135-4144 ◽

Cited By ~ 5

Author(s):

Chaogang Yang ◽

Dongdong Shi ◽

Shuyi Wang ◽

Chen Wei ◽

Chunxiao Zhang ◽

...

Keyword(s):

Colorectal Cancer ◽

Cohort Study ◽

Cancer Patients ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Prospective Cohort Study ◽

Prospective Cohort ◽

Prognostic Value ◽

Curative Resection ◽

Colorectal Cancer Patients

Download Full-text

Usefulness of plasma D-dimer level for monitoring development of distant organ metastasis in colorectal cancer patients after curative resection [Corrigendum]

Cancer Management and Research ◽

10.2147/cmar.s194759 ◽

2018 ◽

Vol Volume 10 ◽

pp. 6325-6326

Author(s):

Yi Guo ◽

Feng Chen ◽

Wei Cui

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Curative Resection ◽

Distant Organ Metastasis ◽

Organ Metastasis ◽

Distant Organ ◽

Colorectal Cancer Patients ◽

D Dimer

Download Full-text

The Effect of miR-145-5p, DANCR and NRAS Expression Levels on the Survival Rate of Colorectal Cancer Patients

Asian Pacific Journal of Cancer Prevention ◽

10.31557/apjcp.2021.22.12.4043 ◽

2021 ◽

Vol 22 (12) ◽

pp. 4043-4049

Author(s):

Fatemeh Bahreini ◽

Masoud Saidijam ◽

Saeid Afshar ◽

Zahra Mousivand ◽

Rezvan Najafi

Keyword(s):

Colorectal Cancer ◽

Survival Rate ◽

Cancer Patients ◽

Expression Levels ◽

Colorectal Cancer Patients

Download Full-text

Log odds of positive lymph nodes as a prognostic indicator in stage IV colorectal cancer patients undergoing curative resection

Journal of Surgical Oncology ◽

10.1002/jso.23855 ◽

2015 ◽

Vol 111 (4) ◽

pp. 465-471 ◽

Cited By ~ 6

Author(s):

Tsuyoshi Ozawa ◽

Soichiro Ishihara ◽

Eiji Sunami ◽

Joji Kitayama ◽

Toshiaki Watanabe

Keyword(s):

Colorectal Cancer ◽

Lymph Nodes ◽

Cancer Patients ◽

Curative Resection ◽

Stage Iv ◽

Prognostic Indicator ◽

Stage Iv Colorectal Cancer ◽

Log Odds ◽

Colorectal Cancer Patients ◽

Positive Lymph Nodes

Download Full-text

Clinical and Socioeconomic Factors that Predict Non-completion of Adjuvant Chemotherapy for Colorectal Cancer in a Rural Cancer Center

The American Surgeon ◽

10.1177/00031348211054708 ◽

2022 ◽

pp. 000313482110547

Author(s):

Chelsea Knotts ◽

Alexandra Van Horn ◽

Krysta Orminski ◽

Stephanie Thompson ◽

Jacob Minor ◽

...

Keyword(s):

Colorectal Cancer ◽

Adjuvant Chemotherapy ◽

Socioeconomic Factors ◽

Cancer Patients ◽

Private Insurance ◽

Stage Ii ◽

Stage Iii ◽

Insurance Status ◽

Complete Treatment ◽

Colorectal Cancer Patients

Background Previous literature demonstrates correlations between comorbidities and failure to complete adjuvant chemotherapy. Frailty and socioeconomic disparities have also been implicated in affecting cancer treatment outcomes. This study examines the effect of demographics, comorbidities, frailty, and socioeconomic status on chemotherapy completion rates in colorectal cancer patients. Methods This was an observational case-control study using retrospective data from Stage II and III colorectal cancer patients offered chemotherapy between January 01, 2013 and January 01, 2018. Data was obtained using the cancer registry, supplemented with chart review. Patients were divided based on treatment completion and compared with respect to comorbidities, age, Eastern Cooperative Oncology Group (ECOG) score, and insurance status using univariate and multivariate analyses. Results 228 patients were identified: 53 Stage II and 175 Stage III. Of these, 24.5% of Stage II and 30.3% of Stage III patients did not complete chemotherapy. Neither ECOG status nor any comorbidity predicted failure to complete treatment. Those failing to complete chemotherapy were older (64.4 vs 60.8 years, P = .043). Additionally, those with public assistance or self-pay were less likely to complete chemotherapy than those with private insurance ( P = .049). Both factors (older age/insurance status) remained significant on multivariate analysis (increasing age at diagnosis: OR 1.03, P =.034; public insurance: OR 1.84, P = .07; and self-pay status: OR 4.49, P = .03). Conclusions No comorbidity was associated with failure to complete therapy, nor was frailty, as assessed by ECOG score. Though frailty was not significant, increasing age was, possibly reflecting negative attitudes toward chemotherapy in older populations. Insurance status also predicted failure to complete treatment, suggesting disparities in access to treatment, affected by socioeconomic factors.

Download Full-text